Biopharma GettyImages-1298364833.jpg
Our Work

Latham & Watkins Advises Zevra Therapeutics in US$100 Million Credit Facility

April 11, 2024
Firm represented the rare disease therapeutics company in debt refinancing and new credit facility.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, has announced that it has entered into a new credit facility provided by leading biotech investors. Led by Perceptive Advisors and Healthcare Royalty, the new credit facility provides up to US$100 million in committed capital in three tranches: an initial draw of US$60 million at closing, a second tranche of up to US$20 million available until October 5, 2025, and a third tranche of up to US$20 million which becomes available upon approval of arimoclomol, the Company’s product candidate for the treatment of Niemann Pick disease Type C (NPC), in each case subject to certain terms and conditions.

Latham & Watkins LLP advised Zevra in the transaction with a deal team led by finance partners Haim Zaltzman and Jennifer Kent, with associates Hyunji Lee, Jessica Lietz, Lindsay Kenney, and Steve Hess. Advice was also provided on certain corporate matters by partners Nathan Ajiashvili, Christopher Clark, Reza Mojtabaee-Zamani, and Eric Rice; on tax matters by partner Aaron Bernstein, with associate Jacob Nagelberg; on intellectual property matters by partner Chris Hazuka, with associates Robert Yeh and Kristina Funahashi; on healthcare regulatory matters by partners Elizabeth Richards and Betty Pang; with associate Nathan Beaton; on data privacy matters by partner Heather Deixler, with associate Heather Lui; on ERISA matters by partner Nikhil Kumar, with associate Bryce Williamson; and on certain other regulatory matters by partners Nathan Seltzer and Joel Cavanaugh and counsel Andrew Galdes.